Harvard Bioscience Statistics Share Statistics Harvard Bioscience has 44.21M
shares outstanding. The number of shares has increased by 1.38%
in one year.
Shares Outstanding 44.21M Shares Change (YoY) 1.38% Shares Change (QoQ) 0.32% Owned by Institutions (%) 58.15% Shares Floating 37.25M Failed to Deliver (FTD) Shares 20 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 1.16M, so 2.63% of the outstanding
shares have been sold short.
Short Interest 1.16M Short % of Shares Out 2.63% Short % of Float 2.85% Short Ratio (days to cover) 1.78
Valuation Ratios The PE ratio is -7.41 and the forward
PE ratio is 8.62.
Harvard Bioscience's PEG ratio is
-0.03.
PE Ratio -7.41 Forward PE 8.62 PS Ratio 0.98 Forward PS 0.2 PB Ratio 1.45 P/FCF Ratio -76.3 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Harvard Bioscience.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.82,
with a Debt / Equity ratio of 0.7.
Current Ratio 0.82 Quick Ratio 0.4 Debt / Equity 0.7 Debt / EBITDA -30.19 Debt / FCF -36.96 Interest Coverage -1.94
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $285.26K Profits Per Employee $-37.59K Employee Count 330 Asset Turnover 0.74 Inventory Turnover 1.69
Taxes Income Tax 740K Effective Tax Rate -6.34%
Stock Price Statistics The stock price has increased by -81.79% in the
last 52 weeks. The beta is 1.55, so Harvard Bioscience's
price volatility has been higher than the market average.
Beta 1.55 52-Week Price Change -81.79% 50-Day Moving Average 0.48 200-Day Moving Average 1.14 Relative Strength Index (RSI) 57.72 Average Volume (20 Days) 12,322,974
Income Statement In the last 12 months, Harvard Bioscience had revenue of 94.14M
and earned -12.4M
in profits. Earnings per share was -0.28.
Revenue 94.14M Gross Profit 54.77M Operating Income -6.21M Net Income -12.4M EBITDA -1.47M EBIT -8.46M Earnings Per Share (EPS) -0.28
Full Income Statement Balance Sheet The company has 4.11M in cash and 44.49M in
debt, giving a net cash position of -40.39M.
Cash & Cash Equivalents 4.11M Total Debt 44.49M Net Cash -40.39M Retained Earnings -158.01M Total Assets 79.8M Working Capital -10.7M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 1.44M
and capital expenditures -2.64M, giving a free cash flow of -1.2M.
Operating Cash Flow 1.44M Capital Expenditures -2.64M Free Cash Flow -1.2M FCF Per Share -0.03
Full Cash Flow Statement Margins Gross margin is 58.18%, with operating and profit margins of -6.6% and -13.18%.
Gross Margin 58.18% Operating Margin -6.6% Pretax Margin -12.39% Profit Margin -13.18% EBITDA Margin -1.57% EBIT Margin -6.6% FCF Margin -1.28%
Dividends & Yields HBIO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for HBIO is $3,
which is 466% higher than the current price. The consensus rating is "Hold".
Price Target $3 Price Target Difference 466% Analyst Consensus Hold Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 4, 2013. It was a
forward
split with a ratio of 1319:1000.
Last Split Date Nov 4, 2013 Split Type forward Split Ratio 1319:1000
Scores Altman Z-Score -4.41 Piotroski F-Score 5
